FDA Clears IMRIS Visius Surgical Theatre Upgrade

 

February 28, 2014
IMRIS Visius Surgical Theatre MRI Systems Angiography Hybrid OR

February 28, 2014 — The U.S. Food and Drug Administration (FDA) cleared IMRIS Inc.’s upgraded Visius Surgical Theatre, which integrates Siemens' high-field MR scanners.

The core imaging technology based on Siemens Aera 1.5T(tesla) and Skyra 3.0T technology helps IMRIS deliver better image quality with higher signal-to-noise ratio. It also provides faster 3-D image acquisition and improved ease-of-use and workflow during neurosurgical procedures using intraoperative MRI (iMRI).

The addition of these MR systems expands the 1.5T and 3.0T MRI choices hospitals have when considering the ceiling-mounted IMRIS solution for intraoperative imaging, which brings the MRI to the patient during the procedure.

The first installation of this new generation Visius Surgical Theatre will be a four-room hybrid operating room suite, known as the Center for Surgical Innovation (CSI) at Dartmouth-Hitchcock Medical Center in Lebanon, N.H. 

The Dartmouth-Hitchcock installation will also include a Visius intraoperative CT (iCT), which utilizes the technology of the 64-slice Siemens Somatom Definition AS scanner, making it an operating suite with both Visius iMRI and iCT modalities able to serve multiple operating rooms without moving the patient.

Inside a Visius Surgical Theatre equipped with either high-field iMRI or iCT, surgeons have on-demand access to real-time data and imaging during the procedure from the OR table.

For more information: www.imris.com